Table 1 Baseline Patient Characteristics
Total Number of Patients | 25 |
|---|---|
Age (years), mean (SD) | 52 (9.9) |
Females (percent) | 22 (88%) |
Race n (%) | |
 Caucasian | 10 (40%) |
 Black | 4 (16%) |
 Hispanic | 5 (20%) |
 Asian | 4 (16%) |
 Other | 2 (8%) |
Seropositive n (%) | 22 (88%) |
Disease Duration (years), mean (SD) | 10.4 (9.7) |
BMI, mean (SD) | 31.0 (10.8) |
Prednisone at Baseline n (%) | 7 (28%) |
csDMARDs at Baseline n (%) | 18 (72%) |
   Methotrexate | 13 (52%) |
   Sulfasalazine | 4 (16%) |
   Hydroxychloroquine | 4 (16%) |
   Leflunomide | 4 (16%) |
bDMARDs before Baseline n (%) | |
 TNF inhibitor | 8 (32%) |
 IL-6 inhibitor | 1 (4%) |
 Anti-CTLA4-IgG | 2 (8%) |
 None of the Above | 14 (56%) |
Comorbidities (number), mean (SD) | 3.8 (2.6) |